Internal

The Moat War Room

Team access only.


Internal · Competitive War Room · Fable 5 · 2026-07-10

The Moat War Room

Four questions, answered plainly: who else is fighting for this market, whether we can actually win it, how big our edge really is, and exactly what to do this year. The honest headline up top: our edge is real and rare, but it comes from WHERE we stand, and there is a clock on it. This year is the window.

17
Competitors mapped
6
Tech companies
6
Healthcare insiders
1
Durable edge today
The Big Picture
Techies vs Insiders
The Competitors
Our Edge
The Pricing Engine
The Plan & Why We Win
The Decision

tip Every glowing ? opens a plain-English deep-dive. Tap them.

The one-sentence answer

Our competitors are mostly tech companies that pointed great data tools at big hospitals and insurers. The healthcare experts built consulting services, not software. Reddenda is the rare team with both skills, aimed at the one customer nobody else will serve: the small independent practice.

Start here

What is this fight even about?

The government forced insurers to publish what they pay every provider, so that data is now public. Everyone in this market is racing to turn it into leverage: proof a practice can take to a payer and say "pay me more." The prize is the provider who wants a better rate. The giants all chased big hospitals and health systems. We picked the slice they ignore: the small practice that has never had a tool like this.

In plain EnglishA "moat" is anything that stops a competitor from copying you and taking your customers. This whole document asks three things: do we have one, how strong is it, and how do we make it stronger.
The board

Who is chasing which customer

Four kinds of players. Notice the empty lane at the bottom.

Player typeWho they sell toTheir priceDo they want OUR customer?
Tech data companies
techie Serif, Trilliant
Other software companies and big enterprises Sell the raw data feed; some give it away free No. They sell the data, not the answer. They do not help anyone negotiate.
Healthcare insiders
insider Aroris, consultants
Hospitals and large groups A cut of whatever they recover (success fee) No. Small practices are too small to bother with, and their model cannot scale down.
Big billing platforms
incumbent athenahealth, Tebra, Waystar
The practices they already host A percent of collections, or $1,000+/mo No. They cannot fight the payers their own business depends on.
Reddenda
both the empty lane
Small independent practices and their billers $0 to $997, flat Yes. That is the entire company. Nobody else is standing here.
In plain English"Whitespace" means an empty part of the market where no competitor is fighting. The small-practice lane is our whitespace: the giants literally cannot price down into it without wrecking their own business.
The honest headline
The edge is real and rare, but it is positional and time-boxed. It does not come from having more money, better data, or better tech than the funded leaders. It comes from standing in the one spot where all of their advantages stop working. That is powerful, and it has a deadline.
Positional, in plain EnglishOur advantage is about WHERE we stand, not how strong we are. We picked the one square on the board where a bigger, richer rival still cannot beat us.
Time-boxed, in plain EnglishThe window is open now, but it will not stay open. Once we show traction, a funded copycat can start its own clock. The one job this year is to move fast and pour the concrete before anyone else wants this square.
The concept that matters most

Techies vs Insiders: which job is harder?

Two kinds of companies are trying to win this market. Tech people who must LEARN healthcare, and healthcare people who must BUILD technology. Whoever clears both jobs first wins. So which job is harder?

The Techies techie
engineers coming into healthcare
The Insiders insider
healthcare experts coming into tech
Great at Building software, parsing giant data files, shipping fast. Knowing how billing, payers, and contracts really work.
Struggle with They do not know what a small biller actually negotiates, or how to stay on the right side of the law. Turning that know-how into real software instead of a hands-on service.
How they cope Sell the raw data and let the customer figure out the rest. Stay a consulting shop and charge a cut of what they recover.
Real examples Serif (built its core in a few months). Trilliant (gives billions of rates away free). Aroris (success-fee negotiation service). MD Clarity (only shipped a product after hiring a tech chief).
Can they win our lane? Only if they ALSO learn the hard domain. Most swerve away. Only if they ALSO build real software. Most never do.
The answer

Building tech is a wall. Learning the domain is a maze.

The tech: a WALL

hard to climb, easy to buy

The data files are genuinely huge and messy. But it is a normal engineering job with a finish line. Serif built its core in a few months. Trilliant gives billions of rates away free. So this wall gets cheaper to climb every year.

What "Trilliant gives billions of rates away free" actually means deep dive

What Trilliant did. In late 2025 Trilliant Health took the raw hospital price files every U.S. hospital must publish, cleaned and stitched them, and gave the whole thing away, three moves in a row: a free AI chatbot (Oria, Oct 16), then a free repository of 5B+ raw rates (Nov 18), then a single free "data lake" you can query from your laptop with 6B+ negotiated rates across 5,000+ hospitals (Dec 4). No servers, no data team needed.

Why would anyone give that away? Because the giveaway is the business. Three motives stacked: lead-gen (free data is the best top-of-funnel into their paid analytics), land-and-expand (the free tier answers easy questions, anything deeper pushes you to the paid product), and salting the earth (if the raw data is free, a rival who sells raw data has nothing left to sell).

What "the wall" is. The wall is the old barrier of acquiring and parsing those giant public rate files, hunting them down source by source and wrestling messy formats into something usable. That used to need a real data-engineering team.

Why it gets cheaper every year. Free lakes like Trilliant's, plus Serif, plus ever-cheaper compute and AI, mean anyone can now clear that wall in an afternoon. So raw rate-data access is becoming a commodity, and a commodity is not a moat.

The honest nuance. Trilliant's free lake is the hospital-published side; our core is the payer-published side (the insurer Transparency-in-Coverage files). Cousins, not twins. But the same wall is falling on both sides at once, so the lesson holds.

The punchline for us. Since the data itself is commoditizing, our durable edge cannot be "we have the data." It has to be the action layer (the signable negotiation memo) and the history our customers create by using it, which no free lake contains. That is the whole point of the "Our Edge" tab.

In plain EnglishBuilding the technology is a wall: hard to climb, but you can pay to get over it. Hire an engineer, or just buy the data. That means it stops being special.

The domain: a MAZE

easy facts, one hard part

The facts are easy: what a billing code is, how the fee schedule works, a weekend of reading. So people underestimate the ONE hard part: knowing what a small biller actually negotiates, what number moves a payer, and how to stay compliant.

In plain EnglishLearning the deep know-how is a maze you cannot buy your way through. The easy facts fool people into thinking the whole thing is easy. It is not.
The twist
The tech companies could have won, and they swerved. Serif, Trilliant, and Rivet all cleared the tech wall. Then they stopped short of the hardest part, the actual negotiation help, and sold data, free files, and simple widgets instead. They walked up to the hard door and turned around. That is our opening.
Where we sit

We have both. Be honest about what that means.

Healthcare + sales brains
David
+
Engineering
the AI build lanes
=
Both, aimed at the empty lane
Reddenda
In plain EnglishHaving both skills is the TICKET TO PLAY, not the win. One rival (Turquoise) also has both. The win is having both AND pointing them at the lane nobody else wants.
The field

Who is actually out there

Fifteen real players. For each one: the actual tools they sell, what they do with the payer-rate data, and how they price it. The pattern to notice (spelled out under the table): almost nobody serves the small independent practice, and not one of them is flat, self-serve pricing.

How to read this field: three archetypes, one empty lane deep dive

Everyone here is one of three kinds of company, and each kind has a built-in reason it cannot serve our customer:

1. Rate-data sellers (Serif, Payerset, Trilliant, Turquoise, Clarify, Definitive, PayerPrice). They clean the public rate files and sell the data, feeds, APIs, dashboards, or give it away to sell analytics on top. They stop at the data. They hand you a spreadsheet, not a signed rate increase, and they sell to other software companies and big enterprises, not to a solo practice.

2. Contract + recovery tools (Rivet, MD Clarity, Aroris). These get closest to us. But they run on a practice's OWN already-signed contracts to find underpayments, aimed at hospitals and groups, or sold as a done-for-you service on a success fee. None is a self-serve memo a solo practice runs before it signs.

3. Billing + RCM platforms (athenahealth, Tebra, Waystar, Candid, Adonis). They run the whole billing office. Most never touch the public rate data at all, and they are paid a percent of what you collect, so they cannot pick a fight with the payers their revenue depends on.

The lane nobody fills: flat-priced, self-serve, no-PHI rate leverage aimed straight at the small independent practice. That is the entire company.

1 · Rate-data sellers

techies + data shops

Clean the public rate files and sell the data, or give it away to sell analytics. Stop at the spreadsheet.

2 · Contract + recovery

insiders

Digitize your OWN contracts, find underpayments, negotiate for you. Hospitals/groups or success-fee service.

3 · Billing + RCM

incumbents

Run the whole billing office. Most never touch the rate data, and charge a percent of collections.

CompanyThe tools they actually sellWhat they do with the rate dataPricing model
Turquoise Health
both LOW
enterprise rate DB + AI contract tools
Clear Rates Data (their master rate database) · Market Intelligence (benchmarking dashboards) · Contract Intelligence (AI reads your payer contracts and models what-if rate scenarios) · Precision Contracting (premium: rate modeling + denials by contract) · AskTQ (AI chat over it) · plus free consumer price-shopping and Medicare/out-of-network pricersCleans the public hospital + payer files into one proprietary "Clear Rates" dataset, then sells it three ways: analytics dashboards, AI contract-negotiation modeling, and a free consumer/compliance layer for lead-gen. Now expanding into processing the payments themselves.Quote-gated enterprise annual. Tiered (Analyze → Contracts → Precision), unlimited users, priced by company type, coverage, and number of contracts. ~$95M raised. Consumer tools free.
Serif Health
techie MED
rate-data wholesaler / API
Signal (no-code app: type a provider/payer/code, see negotiated rates + percentiles) · Signal Ask (AI copilot, beta) · Peer Benchmarks · APIs / Neuron (embed live rates into your own software) · FindCare + Provider Directory APIs · Data Delivery (bulk feed to your warehouse)The "pick-and-shovel" supplier: ingests payer files at huge scale (they cite 350B+ rates a month), normalizes them, and resells the data as a search app, APIs, and bulk feeds to 200+ other software companies. Sells the raw material, not the answer.Quote-gated. No public prices. Custom by product (Signal / API / Data Delivery) and data-access level. Free sample dataset to try.
Trilliant Health
insider MED
analytics + free data lake
Oria (free public AI chatbot for hospital prices) · Free DuckDB data lake (6B+ rates given away at $0) · Rate Benchmarking (paid) · Health Plan Price Transparency Analytics (paid) · National Provider Directory (2.9M+) · Longitudinal Patient Journeys (~300M patients) · Workbench + ExplorerRuns a two-sided model: gives billions of hospital rates away free (chatbot + data lake) to own the top of funnel, then joins payer files to a provider directory + 300M-patient claims and sells the analytics. The giveaway is the marketing (see the Trilliant dive in "Techies vs Insiders").Free tier (Oria + the 6B-rate lake) + quote-gated enterprise analytics subscriptions. No public dollar figures.
Payerset
data MED
rate-data infrastructure
Rate Explorer (self-serve app to compare negotiated rates across payers/providers) · Data Lake (piped into your warehouse) · Standard Charges module (hospital chargemaster analysis) · Price Transparency Algorithm (their ghost-rate-stripping cleaner) · free Payer Compliance ScorecardRefines-and-resells the public files: ingests 100% of published payer + hospital MRFs, de-duplicates and strips "ghost rates," then sells the cleaned data as a self-serve app or a raw warehouse feed. A cleaner data wholesaler.Published pricing (rare here). Rate Explorer priced by hospital bed count; Data Lake is enterprise. One of the few that posts a price.
PayerPrice
data MED
rate benchmarking + free tools
Rate Benchmarking (type a code, see what everyone in your market is paid, by NPI/Tax ID) · Fee Schedule Downloads · Market Outlier Detection · Medicare Comparison (rate as % of Medicare) · Contracted Rates API · Data Share (Snowflake/Databricks) · free public rate explorer + Medicare lookup + 835/837 converter + a negotiation-letter templateSame raw material as us: structures the public files into a searchable rate database and sells lookups, benchmarks, and a feed. Closest to a small-practice benchmark, but stops at "here is the number" plus a generic letter template, no signable memo, no accumulated history.Quote-gated usage-based, set on an onboarding call. Free entry layer (free tools + 100 free API searches).
Rivet Health
both HIGH
RCM suite (now Zelis-owned)
Payer Performance (store your contracts, benchmark your rates vs the market, model renegotiations) · Revenue Diagnostics (AI cash forecast) · Underpayments Management (groups underpaid claims into recovery "projects") · Claim Resolution / Resolve · Denials Prevention · Patient Pricing · MRF solutionThe closest to us. Uses the public TiC files as the external benchmark to compare a practice's own contracted rates against the market, then drives underpayment recovery. But it is a full RCM suite for practices/groups, not a self-serve one-page memo, and it was just absorbed by Zelis (a payer-side giant).Quote-gated annual SaaS. Third-party directories report a starting price around ~$6,000/yr, custom-quoted.
MD Clarity
insider MED
underpayment + estimates
RevFind (stores your signed contracts, catches underpaid/denied claims) · PayerMonitor (AI reads messy payer contracts) · Clarity Flow (patient cost estimates + Good Faith Estimates) · Underpayment + Denial Recovery Services (done-for-you)Does not use the public rate data. Runs entirely on the provider's OWN private contracts and claims to find underpayments, then software plus a human recovery service chase the money. A recovery tool, not a pre-signing negotiation tool.Quote-gated annual (unlimited users). Recovery services are typically a % of the money recovered.
Aroris Health
insider MED
done-for-you negotiation
Aroris360 (their "Revenue Governance OS": contract library, benchmark engine, rate-case builder) · Contract Optimization (audit that flags underpaid codes) · Contract Negotiation (human negotiators do it for you) · Live Claims Monitoring · free 60-second revenue assessmentPools payer rates into a proprietary benchmark they keep in-house to power their own service; they do not sell or give away the data. The product is really the human negotiator, backed by the benchmark.Success fee. A cut of the incremental revenue they negotiate above your current baseline. Not flat, and structurally can't scale down to a solo practice.
Clarify Health
insider LOW
enterprise analytics
Clarify Atlas (the data engine: 300M+ patient lives + rate data) · Meridian (referral/network growth for systems) · Clarify Rates / Rates IQ (the rate-adjacent one) · Networks · Performance IQ · Access (pharma) · GrowthUses the public rate files as ONE input into a big AI enrichment-and-analytics engine (fused with ~500TB of claims), sold to payers, health systems, and pharma. Rate data is an ingredient, not the product; no small-practice surface.Quote-gated enterprise. No list prices anywhere.
Definitive Healthcare
data LOW
commercial intelligence DB
Atlas Dataset (master reference DB) · HospitalView / PhysicianView / ClinicView etc (profiles of every provider) · Atlas All-Payor Claims (billions of claims) · Populi + Monocl + Carevoyance (sales-targeting suites)A "ZoomInfo for healthcare" plus a claims engine. Sells subscription access to provider profiles and claims analytics for sales and marketing targeting. Not a rate-negotiation product at all; adjacent, not competing.Quote-gated annual, priced per named user, a la carte or bundled.
athenahealth
incumbent MED
EHR + billing platform
athenaOne (all-in-one EHR + billing + engagement) · athenaClinicals (EHR) · athenaCollector (billing/PM) · athenaEDI (clearinghouse, 375M+ transactions/yr) · Patient Estimates · Marketplace (add-ons) · AI documentationDoes not touch the public rate data as a product. Runs the practice's billing office end to end. Its only price-transparency page is athenahealth complying with the rule for its own plan.Percent of collections ("no long-term contracts"), quote-gated. Paid a cut of what you collect, so it cannot fight your payers.
Tebra
incumbent LOW
small-practice OS
EHR / EHR+ · Practice Management · Billing & Payments · Contract Rates / Fee Schedules (you type in your OWN rates) · Underpayment monitoring · Patient Engagement · Practice Marketing (ex-PatientPop) · AI staff/reviewsNever touches the public rate data. The only rates in the product are the ones the practice manually types in. Underpayment monitoring compares paid vs your own entered rate. Same customer as us (small practices), opposite tool.Quote-gated per-provider monthly subscription (non-clinical staff free). Bundled/module sales via demo.
Waystar
incumbent LOW
enterprise RCM + clearinghouse
Claim Manager (clearinghouse) · Denial + Appeal Management (AI writes appeals) · Authorization · Eligibility · Patient Estimation · Price Transparency · Coverage Detection · Charge Integrity · AltitudeAI and ~20 more modulesUses contract/rate data internally to power estimates and payment matching, not as a product. A giant enterprise revenue-cycle platform for health systems; the small practice is far below its floor.Quote-gated enterprise, priced by provider count + claim volume + modules, plus clearinghouse per-transaction fees.
Candid Health
techie MED
automated billing (ex-Palantir)
Automation & AI Rules Engine (reverse-engineers each payer's claim quirks) · Smart Claim Autocorrection · Analytics · AR / Denial Automation · RCM API · EDI/ERA + Eligibility · human RCM supportDoes not touch the public rate data. Runs on the provider's own claims and the payer's 835/ERA responses to make billing "touchless." A modern billing engine, not a rate-leverage tool.Percent of collections (~3%, or 3% + ~$6/claim with coding), quote-gated. Raised ~$99.5M.
Adonis
techie LOW
AI revenue-cycle automation
Adonis Intelligence (watches the whole revenue cycle) · Adonis AI Agents (autonomous bots: verify coverage, work denials) · Adonis Orchestration · Epic Connection Hub integrationDoes not touch the public rate data. Works on the provider's own claims, remits, and EHR data (e.g. via Epic) to catch denials/underpayments with AI agents. Enterprise health systems and groups, not solo practices.Quote-gated enterprise, "ROI/outcome-aligned." Raised ~$95M.

"Touches the public rate data" = uses the same federal Transparency-in-Coverage files Reddenda uses. Six of these fifteen do not touch it at all; they run on the practice's own billing data. "Quote-gated" means they publish no price and make you book a sales call. Not one of the fifteen offers flat, self-serve pricing to a solo practice. That empty lane is the company.

The moves so far

Have they done anything about our lane?

Short version: the funded ones moved UP and SIDEWAYS. Nobody came DOWN to the small-practice lane.

They raised money and chased bigger fish. Turquoise $40M Series C (enterprise and payers). Adonis $40M. Candid $52.5M. Garner $118M at a $1.35B valuation (employer health plans). Every dollar aimed ABOVE our $0 to $997 lane.
They gave data away, which proves data is not the moat. Serif shipped a free AI tool (May 2026). Trilliant shipped a free chatbot plus a free 5B-rate data lake (Nov 2025). Giving the data away only confirms the raw data is not what wins.
They bought each other. Zelis took Rivet and Payer Compass. H1 took Ribbon. Definitive bought Populi. This thins the middle and pushes survivors up-market, which WIDENS our empty lane.
The one to watch

The single most dangerous future move

A funded billing-automation company adds a rate-negotiation feature and cross-sells it. Candid (~$99.5M raised) or Adonis (~$95M raised) already sits inside thousands of practices, running their billing. If one bolts on a "negotiate your rates" feature, it does not need to win distribution. It already has the customer's trust and data.
Why it is scaryThey are already inside the practice, with the money to build the know-how and a ready-made way to cross-sell. No cold start.
Why it is beatableThey still have to walk the domain maze from scratch, a billing vendor may not want to pick a fight with payers, and by then our customer history, cost edge, and signed channel are already compounding.
The one early-warning sign: watch for a "managed care contracting" job posting at Candid or Adonis. That is the first visible move, 6 to 12 months before anything ships.
Sorting real from fake

What is actually a moat, and what just sounds like one

We own seven assets. Only some are real edges. Here is the honest verdict on each.

Our assetIs this a real edge?Why
The rate-data platform (our owned data lake)Nice, but everyone can get itAnyone can buy the same public files. BUT we own our copy, so each report costs us pennies while a rival pays a data bill every month.
The RateScore method (local peer median, P90 target)Nice, but everyone can get itA clear, trustworthy way to score a rate. Any funded rival can copy the math.
The action layer (the negotiation memo, the app)
The action layer, in full: what it is, what we have, why it wins, how to do it deep dive

What it is. Everything a practice DOES with the rate data after they see it. Today that means the signable Counteroffer / Leverage Memo (a one-page document a practice takes to a payer to ask for a higher rate) and the app they generate it in, backed by the RateScore. It is the layer between "here is your rate" and "here is a better rate, signed."

What we have NOW. The memo and the app are live, v1. A practice can already run a Snapshot, get a RateScore, and generate a memo. So this is not a from-scratch build, and the table saying "build now" does not mean the tool does not exist.

Then why does it say "build now"? Because the tool is not the moat, the accumulated history behind it is. A rate lookup is forgettable and copyable day one. But two seasons of a practice's OWN confirmed renewal dates, filed appeals, past memos, and RateScore trend is expensive to walk away from and worthless to a rival who starts at zero. "Build now" means start accumulating that history now, not rebuild the memo.

Why it is our strongest edge. Of everything we own, this is the one asset a funded clone cannot buy, copy, or download. They can clone the pricing page and buy the rates in an afternoon (see the Trilliant dive). They cannot copy a customer's two-year outcome history. Every cycle a practice stays, its exit cost compounds and the clone's catch-up cost rises.

How we do it, the actual playbook:

  • Make every artifact write per-NPI state by default (every memo, appeal, and confirmed date leaves a record tied to that practice, counted confirmed-only so the asset stays honest).
  • Price it to deepen the lock, never flatten it: charge per memo/audit (the artifact that creates the history); let Pro accumulate the RateScore timeline; never ship a pure pay-per-report where everything exports and nothing stays.
  • Sign customers fast, on the renewal clock (switching cost only binds customers already on it, so this year the game is base acquisition at speed, especially through billing-company channels).
  • Deepen the memo and app with appeal tracking, outcome logging, renewal reminders, and the confirmed-date graph, so each cycle leaves more un-exportable state than the last.
Have v1. The moat is what it ACCUMULATESThe memo and app already exist. The durable part is not the tool, it is the per-NPI history each cycle leaves behind (confirmed dates, past memos, appeal outcomes, RateScore trend) that a rival starts from zero on. It only locks in customers who are ON it, so sign them fast and keep that history un-exportable.
Counter-positioning (flat price, no patient data, self-serve)Real and durableThe giants literally cannot copy this without breaking their own business. This is the one edge that holds today.
The channel (billing / RCM / MSO partners)A real edge we must BUILD nowOne partner brings a whole roster of practices, and the relationship locks. Not built yet.
The private data pool (customers' real rates)Could become huge laterThe one dataset no public file has. Only works once enough customers contribute. Build it behind a lawyer's review.
RateScore as a brandCould become huge laterBrand takes years. Give the score away free now, cash it in as a standard later.

Not one of the seven is impossible to copy on its own. The defensible thing is the SET, not any single row. That is the next table.

The killer visual

The combination lock

Seven things that, together, make us hard to copy. Any rival has one or two. Only our column is all yes.

7/7

Reddenda is the only company that checks all seven boxes. The next best competitor checks two.

The 7 thingsReddendaTurquoiseSerifathenaRivet
A signable negotiation documentyesnononono
Small-practice self-serveyesnonoyesyes
No patient data neededyesyesyesnono
Flat pricing, never a percentyesnononoyes
The renewal clockyesnononono
The RateScoreyesnononono
Private, customer-created datayesnononono
In plain EnglishAny ONE of these features is copyable. The whole SET, under one roof, aimed at the small practice, is not. That is the moat: the combination, never a single feature.
The honest gap

Where we are behind, and where we are ahead

We are far behind on money and brand. We are far ahead in the one lane their money cannot buy into. Four lines:

vs the giants (Turquoise, Waystar): far behind on money and brand. Not behind on data: we run an owned estate of 41 datasets across 9 domains plus a multi-billion-row rate lake at near-zero marginal cost, and raw scale is commoditizing anyway. Far ahead in the small-practice lane they are locked out of.
"Far behind on data scale" was wrong. Here is the real picture. deep dive

We are not data-poor. Reddenda runs an owned estate of 41 datasets normalized across 9 domains (commercial rates, Medicare and GPCI, hospital charges, Medicaid, and more) on a public-data cost base, plus a multi-billion-row rate lake we own outright, so a report costs us pennies while a rival pays a data bill every month. Most competitors bring two to four siloed datasets. So we are not behind on data. We are behind on money and brand, which is a different problem.

Raw scale is not the moat anyway. Trilliant just gave 6B+ rates away free and Serif processes 350B+ rates a month. If "the most rates" were the edge, they would have won already. They did not, because access is a commodity (see the Trilliant dive). Chasing "more rates than Turquoise" would be fighting on the one axis that does not matter.

The data we ARE ahead on is the data nobody can buy. Our real data edge is forward-looking: the private pool our customers create (their real contracted rates and de-identified paid amounts) and the confirmed renewal-date graph. Neither exists in any public file or any rival's lake. FAIR Health built the largest private US claims database (53B+ records) exactly this way, from voluntarily contributed data no one else could reconstruct.

So the honest gap is two words: money and brand. Not data. We answer money with a pennies-per-report cost base that funds growth without outside capital, and we seed brand by giving the RateScore away free now and cashing it as the standard later.

vs the data sellers (Serif): they could arm a copycat in months. We beat it with our owned lake and the data our customers create, which is not for sale.
vs the billing platforms (athena, Tebra): they own the distribution. We win on fit: flat $399 vs their cut of collections, and a real renewal tool, not a bundled widget.
vs the negotiation cohort (Rivet): the closest race. We win on the full combination lock, moving first this season, and locking the channel.
The one-sentence answer

One flat, self-serve ladder from a $0 score to a $997 audit that no competitor can copy without breaking their own business, sold on the renewal clock, engineered so every purchase leaves behind history a rival starts from zero on. We never charge a percent of your collections, and we never haggle.

Where this pricing model came from deep dive

This is not a guess. It is the winner of a 10-model pricing war room, scored 1 to 100 by a final judge and stress-tested by a devil's advocate. The winning design is called ALMANAC at 90 out of 100, and it beat nine alternatives including a pure membership, a per-report "Carfax" model, a channel-only model, and a single-price model. What follows is that model in plain English.

Honest floor, stated first: every dollar below is modeled, not guaranteed. Today the product has near-zero revenue and the payment rail needs one fix before any of it is real (see the Sprint 0 gate at the bottom). The design is finished; the collection is not.

The components

The ladder: five rungs, one flat currency

Every rung is a flat dollar figure a buyer can read without a sales call. The price rises with the depth of the artifact, never with a percent of your money.

RungPriceWhat you getIts job in the engine
Free Snapshot$0See if a rate gap exists, in about 15 seconds, in your browser. No email, no card, no PHI.The free RateScore. Top of funnel and the brand seed (the "check your credit score" move).
Leverage / Counteroffer Memo$299 onceOne signable one-page memo for a single payer negotiation.The first artifact that creates history. The cheapest way in.
Practice Audit$997 / $697 foundingFull audit across payers, plus the memo and a strategy.The core paid artifact. The anchor value.
Pro$399/moContinuous monitoring, alerts, saved snapshots, renewal support, the accumulating RateScore timeline.The switching-cost engine. Every month deepens the per-NPI history.
Growth (multi-NPI / billing-co / MSO)Schedule a callMulti-location, billing-company, and MSO roll-ups. Never gated, never priced inline.The channel and org lane. One signature onboards a whole roster.
The integrity rule, in plain EnglishOne posted price for everyone, no coupons, no discounts, and never a percent of your collections. That promise is itself a moat: the giants literally cannot make it. It is also the line that keeps us clean under the federal EKRA law, which forbids paying for referrals as a cut of revenue.
Now vs next

What we have today, and what it becomes

What we have NOW

shipped, v1
  • The full ladder exists: Snapshot, Memo, Audit, Pro, Growth.
  • The free RateScore runs in the browser.
  • The memo, audit, and app generate real artifacts.
  • The payment rail is not collecting yet: near-zero revenue, a webhook to fix, a 100%-off coupon to kill.

What it becomes (ALMANAC)

four organs + expansion
  • Renewal watchlist, a registration reason the free Snapshot lacks, times every sale to the buyer's own renewal clock.
  • Annual Rate Review ($2,990/yr), the auto-renew instrument that turns one-time buyers into recurring.
  • Org / roster packs on the Growth lane for billing companies and groups.
  • Per-contract expansion ($599/contract/yr, capped at $2,990), so an account grows by adding payer contracts, not just by finding new logos.
Why the per-contract piece mattersIt fixes our single biggest weakness. Without it, we only grow by signing new customers. With it, an existing customer grows on its own by adding the payer contracts it wants to defend, the way a legal docketing service charges per patent. It is the difference between a leaky bucket and a compounding one.
Why it beats every alternative

We stress-tested ten pricing models. This one won.

Each was scored 1 to 100 and attacked by a devil's advocate. The flat-ladder-plus-organs design took the top score. Here is why the obvious alternatives lose.

The ten contenders and why each fell short deep dive

All ten cleared the legal floor (flat USD, never a percent). They differ on how they grow and how simple they are to buy:

  • ALMANAC (winner, 90): the flat ladder plus renewal organs. Highest believable revenue, keeps every option open, and its floor is the plan we already ratified.
  • DOCKET (89): price by the payer contract. Best growth engine (we grafted this in), but its first-year revenue sits below the base, so it is an add-on, not the base.
  • DESK (89): the "Gartner of provider rates" advisory framing. Great story, but it is the same model with better words, so we adopt the words, not a new model.
  • CHARTER (89): a membership frame. Imports a gym-membership expectation that works against us.
  • CADENCE (88): a Free, $49, $299 ladder. The cheap rung cannibalizes the audit and revenue drops.
  • PULL (86): a $49 "Carfax report." A full-value report for $49 is a roughly 100x arbitrage for people who resell our work.
  • WHOLEBOOK (86): channel-only. Highest ceiling but bets everything on partners we have not signed yet.
  • ROSTER (85): flat annual by size, everything unlimited. Deletes our expansion revenue.
  • PAR (78): one single price for everything. Cannot stretch across a 30x range of willingness to pay.

The verdict: commit to ALMANAC, graft DOCKET's per-contract expansion, borrow DESK's advisory naming and PAR's never-a-percent promise. Confidence roughly 85 to 88 percent.

How the market pricesWho does itSolo practice can buy?Why we are better
Quote-gated enterprise (book a call, custom annual)Turquoise, Serif, Clarify, Definitive, Waystar, Adonis, most of the fieldnoA solo practice never gets past the sales gate. We post the price and let them self-serve in minutes.
Percent of collectionsathenahealth, CandidnoTaking a cut of your money means they cannot fight your payers, and it is a legal minefield. We charge a flat fee and stay clean.
Success fee (a cut of the increase)ArorisnoSuccess fees cannot scale down to a $299 memo; the economics only work on big hospital contracts. Our flat memo does.
Free data, paid analyticsTrilliant, PayerPrice free tiersort ofThey hand you a spreadsheet. We hand you a signable memo and keep your history. The data is the commodity; the action is the product.
Flat, self-serve ladder ($0 to $997, never a percent)Reddenda, aloneyesThe only model a solo practice can actually buy, that a giant cannot copy, and that stays legal by construction.
The value and how fast it grows

What it is worth, and why it compounds

~$584K
Modeled year-2 revenue, base case, not guaranteed. Absolute floor is ~$442K with every add-on switched off.
~99%
Gross margin. Each artifact costs pennies of AI compute on an owned data lake with no data bill.
Per-contract
The expansion atom: accounts grow by adding payer contracts, so revenue climbs without new logos.
$0 CAC
The free score is the funnel and channel partners are the reach, so there is no paid acquisition to fund.
How the growth compounds, in one line: the free RateScore fills the top of the funnel, memos and audits create per-NPI history, Pro accrues that history monthly, per-contract expansion grows each account from inside, and the pennies-per-artifact cost base funds it all with no outside money. Every step feeds the next.
The one gate
None of this revenue is real until Sprint 0 is done. The design is finished. What is not finished is the collection: a live payment webhook, a killed 100%-off coupon, a clean product catalog, and a way to revoke access. The one metric that matters before any projection counts is a single real dollar collected, fulfilled, and revoked end to end. Do not build a new pricing model. Run Sprint 0 and ship this one.
Why this is the honest headlineEvery number on this page is modeled. The binding constraint is not the model, it is the pipe. One quarter of a working payment funnel turns every modeled attach rate here into a measured fact.
Start with the belief
Yes, we can win, and here is the proof. Three concrete reasons, not a pep talk.
$0 to $997
The lane is EMPTY. Giants start at $1,000+/mo and cannot come down without breaking their own business.
Pennies
Our cost to make a report, on an owned data lake with zero ad spend. We profit at prices that would bankrupt a funded copycat.
Compounds
Every month a practice uses us, it piles up its own history a competitor cannot copy. Our lead grows on its own.
The five moves

What we do, and what each move buys us

1. Make customers stick

what it does

Build up each practice's own history (its payers, rates, confirmed dates, past memos) so leaving means starting over from scratch.

Switching cost, in plain EnglishThe pain of leaving. The longer a practice uses us, the more of its own data lives here, and the more it loses by switching. That pain is our lock.
The payoff: a customer who cannot cheaply leave, and a rival who starts every account at zero.

2. Go through billing companies

what it does

Sell to the billing and RCM firms that already run dozens of practices, and onboard their whole roster at once.

The channel, in plain EnglishA "channel" is a partner who sells to their customers for you. One billing-company deal brings a whole roster of practices in a single signature.
The payoff: mass sign-ups from one deal, a locked relationship, and it beats a billing platform to the punch.

3. Build a private data pool

what it does

Let customers share their real, contracted rates in exchange for better benchmarks, creating a dataset nobody can buy.

The flywheel, in plain EnglishEach customer's shared data makes the benchmark better, which attracts more customers, who share more data. It spins faster the more people join.
The payoff: the one dataset a public-file rival can never have, growing every month.

4. Give the score away free

what it does

Make "what's my RateScore?" the normal question a practice asks, the way people ask about their credit score.

The payoff: free top-of-funnel now, and ownership of the category's language for later.

5. Move fast and cheap

what it does

Use our pennies-per-report cost to price below any funded rival and outlast them, funding growth with no outside money.

The payoff: we stay profitable at prices that set a copycat's cash on fire.
How the moat is built and perfected

A moat is not one thing. It is powers you win in a set order.

Every durable advantage has a life-stage where it can be built, and the window closes. The whole discipline is to point our energy at the powers winnable right now, seed the ones that pay off later, and never mistake the floor for the edge.

The power clock: why order is everything deep dive

This comes from Hamilton Helmer's "7 Powers," the standard playbook for durable advantage. His key finding: each kind of moat can only be built at a specific moment, and if you miss the window it is gone.

Origination powers (counter-positioning, a cornered resource) are what a startup is born with. We hold counter-positioning already: flat price and no PHI, which the giants cannot copy without breaking their own model.

Takeoff powers (switching costs, network effects, scale economics) can ONLY be won during fast growth, right now, in the next few quarters, before a funded copycat starts its own clock. None of ours are banked yet. This is the entire job this year.

Stability powers (brand, process) come last. You cannot buy brand late, so you seed it for free now (give the RateScore away) and harvest it once you have a base. Process power (our ghost-rate filtering) is table stakes: keep it sharp, never claim it keeps a funded rival out.

The failure mode Helmer names is spending the takeoff window on the wrong power: chasing brand while unknown, or trying to bolt on switching cost after rivals are entrenched. So we build switching cost and the flywheel NOW, seed brand free, and refuse the distractions.

StagePowers you can build hereWhat we do about it now
Origination (day one)Counter-positioning, cornered resourceAlready held: no-PHI, flat price the giants cannot copy. The private-data flywheel is the cornered resource, still to build.
Takeoff (right now, 2 to 6 quarters)Switching costs, network economies, scale economiesThe entire job this year. None banked yet. This is the winnable set, and the window is open now, before a funded clone starts its own clock.
Stability (later)Branding, process powerSeed the RateScore-as-standard brand now, harvest later. Process power (ghost-filtering) is table stakes, never the edge.
The one discipline that mattersYou can only win switching costs and network effects DURING takeoff, and you cannot buy brand late. So build the switching cost and the flywheel now, seed the brand for free, and refuse to waste the takeoff window on brand spend or an enterprise sales motion. Get the order wrong and the window closes.
The perfect buildout, if I were running it

What I would do now, in order

One connected sequence. Each step feeds the next, and each one banks a specific power. Nothing here waits on outside money.

1
Instrument first (weeks, not quarters).Stand up three meters before the push: per-NPI accumulated history, confirmed-renewal-date coverage, and contributed-data density per local market. A power you cannot measure is just a story. Banks: the ability to prove every power below.
2
Land 3 to 5 anchor channel partners this season.Billing, RCM, and MSO firms, white-labeled, land-and-expand from one NPI to the whole roster, with multi-NPI kept as "schedule a call." One signature onboards dozens of practices. Banks: distribution and mass base acquisition.
3
Flood the action layer.Every roster NPI generates memos, appeals, and confirmed dates that write per-NPI history, counted confirmed-only. Banks: switching cost, compounding every cycle.
4
Open the give-to-get loop behind a lawyer's review.Customers share their real contracted rates and de-identified paid amounts in exchange for better benchmarks. The density meter ticks up per market, toward a dataset no public file has. Banks: the network path to a cornered resource nobody can buy.
5
Run the free RateScore as the standing top of funnel.The free score educates, feeds both self-serve and channel, and makes "what is my RateScore" the default question a practice asks. Seeds: the brand for later.
6
Hold the price floor with tempo.Pennies-per-artifact plus annual-prepaid Pro funds the whole season with no outside capital and keeps prices below any funded clone's floor. Banks: a cost advantage that dictates the clone's strategy.
7
Publish the graphs as the proof.Confirmed-date coverage and contribution density become the fundraise and partnership exhibit, and the thing a clone starts at zero on. Converts: the takeoff powers into a legible, compounding lead.
The end state: by the time a funded clone is even visible (2 to 4 quarters after our motion shows), the three takeoff powers are already banking. It can copy the pricing page and buy the rates. It starts at zero on the switching cost, the channel lock, and the flywheel, and it inherits a cost base it cannot undercut.
The discipline

What we refuse to do this year

A moat is as much what you say no to as what you build. Every one of these is a tempting trap that would cost us the takeoff window.

We refuseBecause
An enterprise / committee sales motionThat is the incumbents' cornered ground ($75K to $350K, procurement-heavy). Chasing it starves the wedge that is actually ours.
A second parallel "big bet"One transformation at a time. Two tear a two-person company apart. The channel is the one; everything else stays small.
Any PHI / BAA featureIt forfeits the no-PHI counter-position, the day-one power the whole strategy rests on. PHI-bound rivals cannot follow us there; do not join them.
Leaky metering (pure pay-per-report, full export, no stored history)It destroys the switching cost. Never price in a way that makes leaving cheap.
Claiming "we have the data" is the moatAccess is a commodity (see the Trilliant dive). Claiming it invites the exact rebuttal a funded rival will make. It is the floor, not the edge.
Brand spend before the base existsBrand is a stability power you cannot buy early. Seed the standard for free now, harvest the brand later off the installed base.
The timeline

The plan, phase by phase

Each phase: one action, one result. Nothing more.

PhaseWhenDo thisThe result
Phase 0weeks 0 to 4Prove the plumbing works and start measuring: stand up the KPIs and smoke-test the payment rail weekly.You can see what is compounding, and you know the payment rail actually works.
Phase 1months 1 to 4Land 3 to 5 billing-company partners, timed to renewal season, and flood them with our documents.A whole roster of practices onboarded at once, each one piling up its own history.
Phase 2months 3 to 9Open the private data pool, behind a lawyer's review.You start building the one dataset nobody can buy.
Phase 3months 6 to 12+Publish the proof and watch the lead compound.By the time a copycat is visible, it starts at zero on everything that matters.
Honest about the risks

What could stop us, and what we do about it

37%
The #1 danger is not a competitor. It is apathy. 37% of small practices never negotiate their payer contracts at all. If nobody bothers, the best product in the world sits unused. So we make the free score effortless, and we sell THROUGH billing companies, who are paid to care.
The riskSo we do this
Practices are lazy about negotiating (37% never do) the biggest oneMake the free score effortless; sell through billing companies who are paid to care.
Our own rail never works, near-zero revenue todayOne goal first: 10 paying practices kept 60 days. Smoke-test the payment rail every week.
A funded rival drops down to our priceRun the season now; bank the customer history they cannot copy; hold the price floor.
Serif arms a copycat with dataWe never sold data as the edge. Our customer-created data is not on Serif's shelf.
A billing platform bundles a rival's widgetBe the tool billing companies white-label FIRST.
Our rate data goes stale (esp. renewal dates)Turn published dates into customer-confirmed dates we own; re-check the data quarterly.
The rallying close
The fear and the strength say the exact same thing. Our biggest fear (apathy and our own cold start) and our biggest strength (an empty, profitable lane nobody can price into) both give one order: get real paying practices through this first renewal season. Speed right now is not just tactics. It is the moat starting to build itself. Let's go pour the concrete.
The capstone question

Is this really our best move? We tested it.

We scored ten different strategies against each other, stress-tested the winner against the real market, and studied the companies that won this exact game before us. Here is what came back.

The answer
0

Confirmed as the best option, about 80% confidence.

Not dethroned by any alternative. It is the only plan that plays the hand we actually hold: an owned data lake that costs us pennies per report, a rare mix of healthcare and engineering skill, two operators plus AI, aimed at the one lane where being richer does not help our rivals win.

The plan, in one breath. Own the small-practice lane nobody serves, reach it through the billing companies, make each practice pile up its own history so it cannot cheaply leave, build a private data pool no one can buy, give the score away to own the category, and move fast on a cost base that bankrupts a funded copycat. We add three upgrades to make it even stronger, below.
The bracket

Ten strategies, one winner

Every path Reddenda could take, scored out of 70 on revenue ceiling, defensibility, speed, cost efficiency, team fit, downside safety, and future options. The order is decisive.

RankStrategyScoreWhy it wins or loses
1Own the small-practice lane recommended56Strong on all three things a two-person-plus-AI team actually has: defensibility, cost efficiency, and team fit. Plays our real hand.
2Start with one specialty first52Fastest to real traction: a narrow beam cuts through apathy. Too small alone, lethal as an add-on. We graft this in.
3Do the negotiation as a flat-fee service43Fastest real cash and makes paid proof, but two operators cap it and it does not build a moat. A season-one bridge only.
4Channel-only white-label42Partners carry the selling, but pure white-label gives up our direct lock-in. The stress test promotes the channel to our spine.
5Build to be acquired early36The buyout wave is real, but building TO flip starves the moat. Keep as a near-free backup posture, never the plan.
6Give everything away free34Right instinct (free the score, we already do), wrong scope. Free-everything at zero revenue starves a bootstrap.
7Sell the raw data (arms dealer)31Monetizes the one asset that is NOT a moat and is commoditizing anyway. It arms our own copycats. Refuse.
8Raise venture and blitzscale28Raising at zero revenue is a dilution trap and blitzscale destroys our pennies-per-report weapon. Refuse now.
9Go up-market / enterprise25Marches into the fortified square we are counter-positioned OUT of, with none of the money that square rewards. Refuse.
10Sell to the insurers22Worst option: it inverts the very thing that makes us special to chase a market owned by giants. Refuse.
The four to flatly refuse. Go up-market, sell to insurers, sell raw data, and raise-and-blitzscale all fail for the same reason: they abandon the one lane we can defend and march onto ground the funded giants already own. Every one of them trades our real advantage for a fight we lose.
Making the winner stronger

Three upgrades to bolt on

Upgrade 1

Lead with one specialty

Point the first renewal season at behavioral health: it is paid roughly $120 to $135 where BCBS pays $180 to $210 on the same session code, it has a federal parity law on our side, and its practices are small and scattered.

In plain EnglishPick the specialty with the biggest, most obvious underpayment so the first pitch is impossible to ignore. The platform still serves everyone; this is just where we start.
The payoff: the sharpest weapon against our #1 risk, that owners are too apathetic to act.
Upgrade 2

Channel first, and stay acquirable

Promote the billing-company channel from one focus to the MAIN motion. Keep clean books and clear data ownership so being bought is a cheap backup plan.

In plain EnglishThe companies buying up independent practices ARE our best sales channel. Selling through them beats knocking on doors, and staying acquirable is a free insurance policy on the same wave.
The payoff: it beats both apathy and the shrinking market at the same time.
Upgrade 3

Find a second check-writer

Our private, de-identified rate pool is a licensing revenue line, the way pharma paid Phreesia (25 to 35% of its revenue) and PBMs paid GoodRx (82% of its contribution). Lawyer-reviewed, no patient data.

In plain EnglishThe data we build can be sold, cleanly, to a second buyer, so the practices themselves can pay less. That is not just a moat, it is a second income stream.
The payoff: revenue that lets us keep prices low and still profit.
The one fact that changes everything
36.1%

The independent practice is a melting ice cube.

As of January 2026, only 36.1% of physicians still own their practice. The rest have been bought up.

0
practices absorbed in 2024 to 2025
0
fewer independent practices than 2018
0
drop in physician ownership since 2018
This is why we move fast, and why we sell THROUGH the buyers. Fought one practice at a time, this shrinking market is a slow loss no matter how well we execute. But the companies doing the absorbing, the billing firms and management groups, are exactly our channel. The same fact that is scary as a door-to-door plan becomes our distribution strategy the moment we sell through them. It is invisible on any competitor chart, and it is the single most decision-changing number in this whole analysis.
The honest part

What must hold, and how we could still lose

Condition 1

A buyer who actually acts

Either the billing company's professional negotiator buys, or a practice owner clears the small cheap-purchase bar. Proven or disproven in one season, by Oct 31, 2026.

Condition 2

Partners sign and stay

3 to 5 channel partners sign and keep white-labeling us instead of building it themselves. Measured by signed agreements, not interest.

Condition 3

We ride the consolidation

We sell to the groups buying practices up, not fight them door to door. Insist on pure direct-to-independent and the shrinking market beats us.

How we could still lose, even doing everything rightOddsWhy it is easy to miss
Owners are simply too apathetic to act, and the market to sell to collapsesHIGHESTA demand problem. It shows up as healthy interest but flat purchases, invisible on any competitor board.
The market consolidates away faster than we can sign practicesMEDIUMThe most under-rated risk. 81,100 fewer independent practices than 2018. A market problem, not a competitor one.
Channel partners refuse, or build their own versionMEDIUMThe firm with the claim stream could buy rate data and build its own benchmark. We have a named sensor for this.
A funded billing-automation company adds negotiation firstMEDIUMCandid or Adonis reaching down into our lane, 12 to 24 months out. We watch their job postings.
The master exit sign, written in advance. By October 31, 2026, if we have fewer than 10 paying practices that stuck for 60 days AND our alert-to-purchase rate is under about 5%, we stop leading with direct sign-ups and go channel-first, with direct becoming free lead-gen only. Deciding this now, before the emotion, is what makes the pivot cheap instead of painful.
How the winners did it

This exact game has been won before

Five companies won Reddenda's shape (an ignored small-business segment, a data-plus-action product, done cheaply through a channel or a data flywheel). Their moves collapse into one sequence.

1
Reach the small guys through a channel.Gusto reached 500,000 small businesses through 18,000 accounting firms instead of selling one at a time. That is our billing-company plan.
2
Give the score away to own the category.Credit Karma made credit scores free, reached 110 million members, and sold to Intuit for $7.1 billion. We give the RateScore away the same way.
3
Build a private data pool no one can rebuild.FAIR Health turned contributions from 75+ sources into 54 billion records nobody can copy. Our customers' real rates become the same un-buyable asset.
4
Own the workflow, not just the data.Toast won by becoming the system the restaurant runs on, after its first version failed. Our action layer, the memos and the renewal clock, is that workflow.
5
Find a second payer so the customer pays less.Phreesia let pharma subsidize the provider side. Our data-licensing line does the same, keeping practice prices low.
And the three mistakes that killed others. Selling "we have the data" with nothing built on top of it (Castlight fell from a $1.7 billion peak to a roughly $370 million exit). Betting the lazy buyer changes behavior on their own (price-transparency tools reached only about 2% adoption). Depending on a single data source that is commoditizing instead of owning the workflow around it. We avoid all three by design.
The one number we run by

The scoreboard

The real fix at the execution level is not a new strategy, it is measurement. The plan was under-instrumented, not under-designed. Here is the dashboard we run the business against.

North Star

Compounding NPIs

A practice counts as "compounding" when it has BOTH a confirmed renewal date AND at least one document we have generated for it. It rises only when the channel, the product, and the data pool all fire together, it leads revenue by a full season, and it is the exact thing a copycat starts at zero on.

0
target by end of 2026 (modeled)
0
target by end of 2027, range 700 to 900 (modeled)
In plain EnglishOne honest number that cannot be faked and cannot be copied. If it climbs, we are winning, months before the revenue shows it. That is the whole game.

The eight signs the plan is working, before revenue shows

SignGreen means
Free signups per week25 or more
Free-to-paid conversion (30 days)above 5% (vs the 5.6% freemium median)
History piled up per practicemore than 3 items
Confirmed renewal dates on fileabove 40%
Channel partners live3 or more
Local data-pool densitymore than 5 filled cells
Checkout completion (the rail works)above 85%
Practices still here after 60 daysabove 80% (43% of small-biz losses hit in the first 90 days)

First 30 days

1
Prove the plumbing.Smoke-test the whole payment path end to end, weekly. If it is not working by week 2, everything else stops.
2
Turn on the meters.Stand up the three measurements and the season alert engine; build a verified list of 20 billing firms.
3
Start the calls.Open channel outreach, book and run 5 discovery calls, put the free RateScore at the top of the funnel.

First 90 days

1
Sign the partners.Turn interest into 3 to 5 signed, flat-fee, compliant channel deals, timed to the late-summer renewal peak.
2
Flood them with documents.Onboard their whole roster; every memo and confirmed date writes history a rival cannot copy.
3
Hit the milestone.10 paying practices retained past 60 days, North Star above 150, and the first proof graphs published.

Modeled math, bottom-up from the funnel: a green year one lands roughly $120K to $200K, exiting around $150K to $220K of run-rate. A green year two lands roughly $600K to $1.2 million, driven by expansion off the year-one base. The honest downside is named too (roughly $30K to $60K), and because the scoreboard shows it in weeks, the pivot stays cheap.

The bottom line
We did not just pick this path. We beat nine others with it. We stress-tested it against the real market, and confirmed it is exactly how the winners of this game did it before us. The strategy question is settled. What is left is one number, Compounding NPIs, and one season to make it climb. Everything else is noise. Let's go get the first ten.